Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial Meeting Abstract
| Authors: | Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; Odenike, O.; Patel, P.; Collins, R. H.; Madanat, Y. F.; Kovacsovics, T.; Deininger, M. W.; Smith, C.; Olin, R. L.; Arellano, M. L.; Blum, W. G.; Schiller, G. J.; Lin, T. L.; Foster, M. C.; Boyiadzis, M. M.; Redner, R. L.; Al-Mansour, Z.; Curran, E. K.; Heerema, N. A.; Gana, T. J.; Martycz, M.; Rosenberg, L.; Marcus, S.; Yocum, A. O.; Chen, T.; Stefanos, M.; Druggan, F.; Burd, A.; Levine, R. L.; Druker, B. J.; Byrd, J. C.; Mims, A. S. |
| Abstract Title: | Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6200 |
| End Page: | 6203 |
| Language: | English |
| ACCESSION: | WOS:000893223206095 |
| DOI: | 10.1182/blood-2022-167316 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work